The European Vasculitis Society 2016 Meeting Report

Research output: Contribution to journalArticle

Authors

  • Ingeborg M. Bajema
  • Jan A. Bruijn
  • Alina Casian
  • Maria C. Cid
  • Elena Csernok
  • Emma Van Daalen
  • Thomas Hauser
  • Raashid A. Luqmani
  • Alfred Mahr
  • Cristina Ponte
  • Alan Salama
  • Mårten Segelmark
  • Kazuo Suzuki
  • Jan Sznajd
  • Y.k. Onno Teng
  • Augusto Vaglio
  • Kerstin Westman
  • David Jayne

Colleges, School and Institutes

External organisations

  • Department of Pathology, Leiden University Medical Center

Abstract

The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.

Details

Original languageEnglish
Pages (from-to)1018-1031
JournalKidney International Reports
Volume2
Issue number6
Early online date21 Sep 2017
Publication statusPublished - Nov 2017

Keywords

  • ANCA , renal outcome , therapy , vasculitis